Drug Trial Radar · NCT06613685
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
73
Actual
Start
Oct 21, 2024
Primary completion
Mar 16, 2026
Study completion Mar 16, 2026
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Sep 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the experimental drugs lepetegravir (formerly GS-1720) (an oral, long-acting integrase strand transfer inhibitor (INSTI)) and lenacapavir pacfosacil (formerly GS-4182) (a prodrug of Lenacapavir (LEN)); to compare the combination of lepetegravir and lenacapavir pacfosacil with the current standard-of-care treatment bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (Biktarvy), to see if the combination of lepetegravir and lenacapavir pacfosacil is safe and if it works for treating human immunodeficiency virus type 1 (HIV-1) infection in treatment-naive people with HIV-1 (PWH). This study has two phases: Phase 2 and Phase 3. The primary objectives of this study are: Phase 2: To evaluate the efficacy of oral weekly lepetegravir coadministered with lenacapavir pacfosacil versus continuing Biktarvy (BVY) in treatment-naive PWH at Week 24. Phase 3: To evaluate the efficacy of oral weekly lepetegravir/lenacapavir pacfosacil fixed-dose combination (FDC) tablet regimen versus continuing BVY in treatment-naive PWH at Week 48.
Conditions
- HIV-1-infection
Interventions
lepetegravirDrug
Tablets administered orally without regard to food
lenacapavir pacfosacilDrug
Tablets administered orally without regard to food
Bictegravir/emtricitabine/tenofovir alafenamideDrug
Tablets administered orally without regard to food
lepetegravir/lenacapavir pacfosacil FDCDrug
Tablets administered orally without regard to food
Placebo to Match BVYDrug
Tablets administered orally without regard to food
Placebo to Match GS1720/GS-4182 FDCDrug
Tablets administered orally without regard to food
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the United States (US) Food and Drug Administration (FDA)-defined Snapshot AlgorithmTime frame: Week 24
- Phase 3: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 48
Locations
58 sites in 9 countries. Site status is shown where the registry gives one.
UAB 1917 Research Clinic
Birmingham, Alabama
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Mills Clinical Research
West Hollywood, California
Georgetown University Medical School
Washington D.C., District of Columbia
Midland Florida Clinical Research Center, LLC
DeLand, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
Floridian Clinical Research, LLC
Miami Lakes, Florida
Orlando Immunology Center
Orlando, Florida
Triple O Research Institute, P.A.
West Palm Beach, Florida
Emory University Hospital Midtown Infectious Disease Clinic
Atlanta, Georgia
Mercer University, Department of Internal Medicine
Macon, Georgia
University of Mississippi Medical Center
Jackson, Mississippi
Saint Michael's Medical Center
Newark, New Jersey
NYU Langone Health Vaccine Center
New York, New York
Medical University of South Carolina (MUSC) Research Nexus
Charleston, South Carolina
St Hope Foundation, Inc.
Bellaire, Texas
Prism Health North Texas, Aids Arms
Dallas, Texas
North Texas Infectious Diseases Consultants, PA
Dallas, Texas
Texas Centers for Infectious Disease Associates
Fort Worth, Texas
UT Health San Antonio
San Antonio, Texas
MultiCare Rockwood Main Clinic
Spokane, Washington
Clinique Médicale L'Actuel
Montreal, Canada
Chronic Viral Illness Service / McGill University Health Centre
Montreal, Canada
Ottawa Hospital Research Institute
Ottawa, Canada
Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I, Immunologische Studienambulanz
Bonn, Germany
Universitätsmedizin Essen, Universitätsklinikum Essen, Klinik für Dermatologie, Venerologie und Allergologie, HPSTD-Ambulanz
Essen, Germany
ICH Study Center GmbH & Co. KG
Hamburg, Germany
Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie, Gebäude K14
Hanover, Germany
Klinikum rechts der Isar, Technische Universität München, Klinik und Poliklinik für Innere Medizin II
München, Germany
Wojewódzki Szpital Obserwacyjno-Zakaźny im. Tadeusza Browicza
Bydoszcz, Poland
Punkt Zdrowia
Gdansk, Poland
Samodzielny Publiczny Wojewódzki Szpital Zespolony w Szczecinie
Szczecin, Poland
Unidade Local de Saude de Amadora Sinatra EPE, Hospital Prof. Doutor Fernando Fonseca
Amadora, Portugal
Unidade Local de Saúde de Lisboa Ocidental E.P.E. - Hospital Egas Moniz
Lisbon, Portugal
Unidade Local de Saúde de Santo Maria E.P.E. - Hospital Santa Maria
Lisbon, Portugal
Unidade Local de Saúde de Santo António, E.P.E.
Porto, Portugal
Unidade Local de Saúde de São João E.P.E.
Porto, Portugal
HOPE Clinical Research
San Juan, PR, Puerto Rico
Proyecto ACTU
San Juan, PR, Puerto Rico
Institutul National De Boli Infectioase Prof. Dr. Matei Bals
Bucharest, Romania
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.